Get the Stockscreener App
47.61
0.02%
0.010
After Hours:
47.60
-0.010
-0.02%
Tourmaline Bio Inc stock is traded at $47.61, with a volume of 988.23K.
It is up +0.02% in the last 24 hours and up +121.65% over the past month.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
See More
Previous Close:
$47.60
Open:
$47.62
24h Volume:
988.23K
Relative Volume:
1.57
Market Cap:
$1.22B
Revenue:
-
Net Income/Loss:
$11.77M
P/E Ratio:
82.30
EPS:
0.5785
Net Cash Flow:
$-19.23M
1W Performance:
+78.05%
1M Performance:
+121.65%
6M Performance:
+192.62%
1Y Performance:
+167.32%
1-Day Range:
$47.59
$47.70
1-Week Range:
$26.31
$47.70
52-Week Range:
$11.56
$47.70
Tourmaline Bio Inc Stock (TRML) Company Profile
Name
Tourmaline Bio Inc
Sector
Industry
Phone
646-481-9832
Address
27 WEST 24TH STREET, NEW YORK
Compare TRML with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
47.61 | 1.22B | 0 | 11.77M | -19.23M | 0.5785 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Nov-11-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-15-23 | Initiated | Jefferies | Buy |
| Dec-04-23 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Oct-31-23 | Initiated | Guggenheim | Buy |
| Oct-25-23 | Initiated | Piper Sandler | Overweight |
| Oct-20-22 | Initiated | H.C. Wainwright | Buy |
| Jul-05-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
View All
Tourmaline Bio Inc Stock (TRML) Latest News
Why Tourmaline Bio Inc. stock could outperform in 20252025 Investor Takeaways & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Tourmaline Bio Updates Executive Severance Plan - TipRanks
Tourmaline Bio stock hits 52-week high at 47.69 USD By Investing.com - Investing.com Australia
Tourmaline Bio (NASDAQ:TRML) Sees Strong Trading VolumeHere's What Happened - MarketBeat
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline - MSN
Truist Financial Downgrades Tourmaline Bio (NASDAQ:TRML) to Hold - MarketBeat
Guggenheim Reiterates "Neutral" Rating for Tourmaline Bio (NASDAQ:TRML) - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Stock Rating Lowered by Chardan Capital - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Lowered to "Neutral" Rating by HC Wainwright - MarketBeat
Novartis to Buy US Biotech Tourmaline Bio for $1.4 Billion - MSN
American Century Companies Inc. Raises Stake in Tourmaline Bio, Inc. $TRML - MarketBeat
Novartis to Buy Tourmaline Bio for $48 Per Share in Cash - MSN
Adage Capital Partners GP L.L.C. Sells 100,000 Shares of Tourmaline Bio, Inc. $TRML - MarketBeat
Lifesci Capital Downgrades Tourmaline Bio (NASDAQ:TRML) to Hold - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Cut to "Hold" at Jefferies Financial Group - MarketBeat
Novartis adds late-stage anti-inflammatory asset with $1.4 billion Tourmaline Bio acquisition - DOTmed
Biotech Stocks To ConsiderSeptember 9th - MarketBeat
Tourmaline Bio Merges with Novartis for $1.4 Billion - MSN
Hsbc Holdings PLC Acquires Shares of 10,357 Tourmaline Bio, Inc. $TRML - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Shares Gap UpStill a Buy? - MarketBeat
TOURMALINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc.TRML - FinancialContent
Piper Sandler Downgrades Tourmaline Bio to Neutral From Overweight, Lowers Price Target to $48 From $65 - MarketScreener
Tourmaline Bio (NASDAQ:TRML) Stock Rating Lowered by Wedbush - MarketBeat
Octagon Capital Advisors LP Invests $13.77 Million in Tourmaline Bio, Inc. $TRML - MarketBeat
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $50.14 Consensus Target Price from Brokerages - MarketBeat
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) - Novartis
Novartis Acquires Tourmaline Bio for $1.4 Billion | - openPR.com
Best Medical Stocks Worth WatchingSeptember 9th - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Hits New 52-Week HighStill a Buy? - MarketBeat
Jefferies Downgrades Tourmaline Bio to Hold From Buy, Adjusts Price Target to $47.50 From $64 - MarketScreener
Novartis to Buy Tourmaline Bio for $1.4 B, Adding Inflammation Drug to Pipeline - HDFC Sky
Novartis Secures $1.4 Billion Deal to Acquire Tourmaline Bio - Vocal
Wild Moves In Stocks From Crypto Plans, Deal News, And A Name Drop - Finimize
Tourmaline steers CV disease asset into $1.4B Novartis sale - biocentury.com
Health Care Up on Deal Activity -- Health Care Roundup - MarketScreener
Novartis to Acquire Tourmaline Bio in $1.4 Billion Deal - Yahoo Finance
Novartis buying Tourmaline and its anti-IL-6 cardio drug for $1.4B - BioWorld MedTech
Tourmaline Bio Stocks Soar Amid Promising Results - timothysykes.com
Jefferies downgrades Tourmaline Bio stock to Hold following Novartis acquisition - Investing.com Canada
Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More Movers - Barron's
Big Gains And Big Losses Shape A Busy Day For Healthcare Stocks - Finimize
Novartis To Acquire Tourmaline Bio in $1.4B Deal to Boost Heart Drug Pipeline - USA Herald
Buyout Of Tourmaline By Novartis Primarily On Pacibekitug IL-6 Novel Mode Of Action (TRML) - Seeking Alpha
Tourmaline Bio To Be Acquired By Novartis AG For $1.4 Billion - citybiz
Novartis to gain heart drug in $1.4B deal for Tourmaline Bio - BioPharma Dive
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Tourmaline Bio Inc Stock (TRML) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):